Roswell Park Cancer Institute clinical trial pipeline

5 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 2 with minor changes only.

1. Notable

   Fluorescence Image Guided Surgery Followed by Intraoperative…Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control · Locally Advanced or Recurrent Colorectal Cancer

   Primary and study completion pushed from Jun 1, 2027 to Jun 1, 2029

   Roswell Park Cancer Institute·Phase 1/2· NCT06307548· Registry history of NCT06307548 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

2. Notable

   Belantamab Mafodotin and Lenalidomide · Multiple Myeloma in…Belantamab Mafodotin and Lenalidomide · Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

   Primary completion pushed from Oct 21, 2026 to Jul 29, 2027

   Also in this update: Study completion moved earlier from Sep 1, 2029 to Jul 29, 2027; and 1 more change in the last 30 days

   Roswell Park Cancer Institute·Phase 2· NCT04876248· Registry history of NCT04876248 on ClinicalTrials.gov (opens the registry)

   Sep 25, 2026

3. Notable

   Pembrolizumab Every 12 Weeks Versus Every 3 Weeks · Non-small…Pembrolizumab Every 12 Weeks Versus Every 3 Weeks · Non-small Cell Lung Cancer

   Results posted: Sep 21, 2026

   Also in this update: Study completion pushed from Jun 14, 2026 to Sep 14, 2026

   Roswell Park Cancer Institute·Phase 2· NCT04032418· Registry history of NCT04032418 on ClinicalTrials.gov (opens the registry)

   Sep 21, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.